Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Yinghong Wang, MD,PHD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objectives: To assess the efficacy of ustekinumab for clinical remission/response of immune-related diarrhea and/or colitis To assess the efficacy of ustekinumab in reducing fecal calprotectin levels Secondary Objectives: To assess steroid free IMDC remission by week 4 and 8 To assess the IMDC recurrence by week 4 and 8 To assess the time duration to IMDC recurrence and overall survival To assess the efficacy of ustekinumab to achieve endoscopic remission of immune-related diarrhea and/or colitis To identify immune signatures related to GI irAEs and those specific to responsiveness to ustekinumab To identify pro-inflammatory immune signatures in serum To assess patient symptom and QOL
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted